In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...

Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

New Understanding of the Gut Immune System May Hold Promise ... (IBD), which occurs in one of two forms: Crohn's disease or ulcerative colitis. Though the two have similar symptoms, they require ...

Janus kinase (JAK) inhibitors can quickly and effectively manage ulcerative colitis (UC), especially when more conventional treatments haven’t worked. UC is a type of inflammatory bowel disease ...

Resilience has characterized many people who have dealt with chronic health challenges, and it would be hard to find someone ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

An international study led by the University of Oulu and Oulu University Hospital has identified six genetic regions ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...